235 related articles for article (PubMed ID: 32521890)
21. Clinical efficacy of TACE combined with Apatinib in the treatment of advanced hepatocellular carcinoma.
Zhu Y; Feng B; Mei L; Sun R; Guo C; Zhu J
J BUON; 2019; 24(2):608-614. PubMed ID: 31128013
[TBL] [Abstract][Full Text] [Related]
22. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial.
Park JW; Kim YJ; Kim DY; Bae SH; Paik SW; Lee YJ; Kim HY; Lee HC; Han SY; Cheong JY; Kwon OS; Yeon JE; Kim BH; Hwang J
J Hepatol; 2019 Apr; 70(4):684-691. PubMed ID: 30529387
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and Safety of Transarterial Chemoembolization Combined With Anlotinib for Unresectable Hepatocellular Carcinoma: A Retrospective Study.
Guo W; Chen S; Wu Z; Zhuang W; Yang J
Technol Cancer Res Treat; 2020; 19():1533033820965587. PubMed ID: 33089769
[TBL] [Abstract][Full Text] [Related]
24. Sunitinib versus sorafenib plus transarterial chemoembolization for inoperable hepatocellular carcinoma patients.
Xu Q; Huang Y; Shi H; Song Q; Xu Y
J BUON; 2018; 23(1):193-199. PubMed ID: 29552783
[TBL] [Abstract][Full Text] [Related]
25. Sorafenib With and Without Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma With Main Portal Vein Tumor Thrombosis: A Retrospective Analysis.
Zhang Y; Fan W; Wang Y; Lu L; Fu S; Yang J; Huang Y; Yao W; Li J
Oncologist; 2015 Dec; 20(12):1417-24. PubMed ID: 26446238
[TBL] [Abstract][Full Text] [Related]
26. The long-term efficacy and safety of apatinib are inferior to sorafenib in the first-line treatment of advanced hepatocellular carcinoma: A systematic review and meta-analysis.
Li D; Zhang C; Yang K; Ma Z; Ma L; Cheng C; Xu L; Wan S
Medicine (Baltimore); 2024 Jan; 103(3):e36865. PubMed ID: 38241568
[TBL] [Abstract][Full Text] [Related]
27. Analysis and prediction of the efficacy and influencing factors of camrelizumab combined with TACE and sorafenib in the treatment of advanced hepatocellular carcinoma.
Pan S; Zheng J; Shi C
J Cancer Res Clin Oncol; 2023 Oct; 149(13):12479-12487. PubMed ID: 37450029
[TBL] [Abstract][Full Text] [Related]
28. Efficacy and safety of radiotherapy plus anti-PD1 versus transcatheter arterial chemoembolization plus sorafenib for advanced hepatocellular carcinoma: a real-world study.
Li JX; Deng WX; Huang ST; Lin XF; Long MY; Zhang J; Su TS; Li LQ; Pang YD; Liang CF; Zhou HM; Lu HY; Liang SX; Xiang BD
Radiat Oncol; 2022 Jun; 17(1):106. PubMed ID: 35690773
[TBL] [Abstract][Full Text] [Related]
29. CalliSpheres drug-eluting beads versus lipiodol transarterial chemoembolization in the treatment of hepatocellular carcinoma: a short-term efficacy and safety study.
Wu B; Zhou J; Ling G; Zhu D; Long Q
World J Surg Oncol; 2018 Mar; 16(1):69. PubMed ID: 29587773
[TBL] [Abstract][Full Text] [Related]
30. Assessment of disease control rate and safety of sorafenib in targeted therapy for advanced liver cancer.
Zeng D; Yu C; Chen S; Zou L; Chen J; Xu L
World J Surg Oncol; 2024 Apr; 22(1):93. PubMed ID: 38605359
[TBL] [Abstract][Full Text] [Related]
31. Prognostic Factors for Survival After Transarterial Chemoembolization Combined with Sorafenib in the Treatment of BCLC Stage B and C Hepatocellular Carcinomas.
Ni JY; Kong J; Sun HL; Chen YT; Luo JH; Wang WD; Chen D; Jiang XY; Xu LF
Acad Radiol; 2018 Apr; 25(4):423-429. PubMed ID: 29198946
[TBL] [Abstract][Full Text] [Related]
32. The Prognosis of Hepatocellular Carcinoma Treated with Sorafenib in Combination with TACE.
Kimura Y; Kaneko R; Yano Y; Kamada K; Ikehara T; Nagai H; Sato Y; Igarashi Y
Asian Pac J Cancer Prev; 2020 Jun; 21(6):1797-1805. PubMed ID: 32592380
[TBL] [Abstract][Full Text] [Related]
33. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: The SPACE trial.
Lencioni R; Llovet JM; Han G; Tak WY; Yang J; Guglielmi A; Paik SW; Reig M; Kim DY; Chau GY; Luca A; Del Arbol LR; Leberre MA; Niu W; Nicholson K; Meinhardt G; Bruix J
J Hepatol; 2016 May; 64(5):1090-1098. PubMed ID: 26809111
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombus: A Systematic Review and Meta-Analysis.
Deng J; Liao Z; Gao J
Curr Oncol; 2023 Jan; 30(1):1243-1254. PubMed ID: 36661745
[TBL] [Abstract][Full Text] [Related]
35. Transarterial Infusion of Epirubicin and Cisplatin Combined With Systemic Infusion of 5-Flurouracil Versus Sorafenib for Hepatocellular Carcinoma With Refractoriness of Transarterial Chemoembolization Using Doxorubicin.
Yoo SH; Kwon JH; Nam SW; Lee JY; Kim YW; Shim DJ; Lee SW; Jang JW
Cancer Control; 2020; 27(2):1073274820935843. PubMed ID: 32583687
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization.
Lee S; Kang JH; Kim DY; Ahn SH; Park JY; Kim BK; Kim SU; Han KH
Hepatol Int; 2017 May; 11(3):292-299. PubMed ID: 28324324
[TBL] [Abstract][Full Text] [Related]
37. Evaluation of the efficacy of aparatinib and carrilizumab combined with transcatheter arterial chemoembolization in the treatment of primary hepatocellular carcinoma.
Chen C; Duan XT; Li GY; Hao XJ; Wang WL; Shen YF; Zhang SH
Eur Rev Med Pharmacol Sci; 2023 May; 27(9):4135-4144. PubMed ID: 37203839
[TBL] [Abstract][Full Text] [Related]
38. Which is the best combination of TACE and Sorafenib for advanced hepatocellular carcinoma treatment? A systematic review and network meta-analysis.
Feng F; Jiang Q; Jia H; Sun H; Chai Y; Li X; Rong G; Zhang Y; Li Z
Pharmacol Res; 2018 Sep; 135():89-101. PubMed ID: 29959032
[TBL] [Abstract][Full Text] [Related]
39. Combination of transarterial chemoembolization and sorafenib improves outcomes of unresectable hepatocellular carcinoma: an updated systematic review and meta-analysis.
Jin PP; Shao SY; Wu WT; Zhao XY; Huang BF; Fu QH; Que RS; Hu QD
Jpn J Clin Oncol; 2018 Dec; 48(12):1058-1069. PubMed ID: 30272196
[TBL] [Abstract][Full Text] [Related]
40. The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study.
Yang Z; Chen G; Cui Y; Xiao G; Su T; Yu J; Zhang Z; Han Y; Yang K; Jin L
Cancer Biol Ther; 2019; 20(3):321-327. PubMed ID: 30332553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]